Determination of finasteride, indapamide and tiemonium methyl sulphate using surface plasmon resonance band of silver nanoparticles. Rev. Sep. Sci. Mohamed Ayad M et al. 20 Oct 2019. RSS-2019-7-2/R2 | Download PDF | Regular article.
A simple and sensitive method was developed for spectrophotometric determination of finasteride, indapamide and tiemonium methyl sulphate in their pure form and in their pharmaceutical formulations. It was found that the studied drugs have the ability to reduce silver nitrate to silver nanoparticles (Ag NPs) in presence of sodium citrate as a stabilizing agent. Silver nanoparticles (Ag NPs) produce a very intense surface plasmon resonance peak at 423 nm that allows quantitative determination of the studied drugs. The calibration curves were linear with concentrations range of 0.50–5.00, 0.50-5.00 and 0.30-2.00 µg/mL for finasteride, indapamide and tiemonium methyl sulphate, respectively. The proposed method was successfully applied to determination of the studied drugs in their pharmaceutical formulations. Furthermore, content uniformity testing of the studied pharmaceutical tablets was also conducted.
Multi-Omics for biomedical applications.
J. Appl. Bioanal. 22 April 2020. Sharif Khan M and Azmir Jannatul. JAB-2020-2-3/R1 |Download PDF | Special Issue “Omics and Multi-Omics for biomedical applications“.
Multi-omics is a rising filed in –omics science. Despite progress in the multiple single –omics platform, the holistic look at the complex nature of the human cell, disease, and other biochemical pathways remain undiscovered. The multi-omics is considered the most integrated system currently available to obtain and measure the biochemical data-driven information for biomedical problems. The current review will look at the factors that play important roles in the rise of the multi-omics field and its application in biomedical studies.
An LC-MS/MS assay for the simultaneous quantitation of thromboxane B2 and prostaglandin E2 to evaluate cyclooxygenase inhibition in human whole blood
J. Appl. Bioanal. 16 June 2020. Shi Y, Murrey HE, Ahn K, Weng N, Patel S. JAB-2020-5-1/R1 |Download PDF | Regular Article
Objectives: A high-throughput LC-MS method for TXB2 and PGE2 was developed for human whole blood assay for COX inhibition. Methods: A surrogate analyte approach was used for the quantitation of TXB2 and PGE2 by LC-MS. Fifty microliters plasma was processed using solid-phase extraction. TXB2-d4 and PGE2-d4 were used as surrogate analytes. The calibration curves were established for TXB2 from 0.1 to 500 ng/mL and for PGE2 from 0.05 to 500 ng/mL. TXB1 was used as internal standard. Results: The response factor and parallelism between surrogate and authentic analyte were verified. Heparinized whole blood assay for COX inhibition was optimized for sample pretreatment, stimulant concentration and incubation time. Conclusion: The LC-MS assay was successfully used to analyze inhibitory activity of four commercially available COX inhibitors. The presented method offers a sensitive, high throughput and low-cost alternative to ELISA for human whole blood assay for COX inhibition.
Clinical Applications of Circulating Tumor DNA, Circulating Tumor Cells, and Exosomes as Liquid Biopsy-Based Tumor Biomarkers
J. Appl. Bioanal. 27 June 2020. Yan A, Yeh C, Zou L. JAB-2020-4-1/R1
Download PDF | Review
Along with improved knowledge of cancer biology and biotechnical progress, the diagnostic approaches have evolved from tissue biopsies to liquid biopsies. As they provide a minimally invasive tumor detection, liquid biopsies allow early diagnosis and serial assessments of tumor progression. Discovery and use of circulating tumor markers circulating tumor DNA (ctDNA), circulating tumor cells (CTC), and exosomes have largely expanded the possibility of early diagnosis of cancer, patient stratification, as well as developing a personalized treatment. Based on these circulomes, liquid biopsies can be developed, but each type of liquid biopsies has its own merits and limitations. While ctDNA-based methods represent the most advanced techniques, sensitivity improvement is expected given the rarity of ctDNA in circulation. As intact cancer cells, CTC provide information on cancer cells. However, current CTC capturing procedures are still lack of efficiency. Exosomes are abundant, but they are highly heterogeneous and there is a lack of specific markers for identification. Future efforts are needed to improve operational parameters and clinical performance of each method. Prior to a broad use in clinical settings, it is crucial to standardize the procedure for the specific liquid biopsy method and validate the test with adequate specificity and sensitivity for clinical applications